N-acetyl-S-farnesyl-L-cysteine (AFC) is the minimal substrate for the enzyme isoprenylcysteine carboxyl methyltransferase (Icmt). A series of amide-modified farnesylcysteine analogs were synthesized and screened against human Icmt. From a 23-member library of compounds, six inhibitors were identified and evaluated further. The adamantyl derivative 7c was the most potent inhibitor with an IC 50 of 12.4 μM.Numerous proteins are initially synthesized with a C-terminal -CaaX box motif, where -C is cysteine, -aa are generally two aliphatic residues, and -X is typically S, M, F, Q, or L. This motif labels the protein for a series of sequential post-translational modifications ( Figure 1). First, either a 15-carbon farnesyl or 20-carbon geranylgeranyl group is added via a thioether linkage to the cysteine by one of two soluble isoprenyltransferases (proteinfarnesyltransferase, FTase, or protein-geranylgeranyltransferase I, GGTase I). Following the attachment of the prenyl group, the three -aaX residues are cleaved by the endoprotease Ras-converting enzyme 1 (Rce1), and subsequently the newly exposed cysteine carboxyl group is methylated by isoprenylcysteine carboxyl methyltransferase (Icmt). It is estimated that at least 120 mammalian proteins undergo this sequential three step post-translational modification sequence, 1 the sum of which typically results in increased hydrophobicity and enhanced membrane association of an initially cytosolic protein.This post-translational pathway became the subject of intense scrutiny as a target for cancer therapies, as it was determined that the oncogenic Ras family of GTPases must be farnesylated in order to properly function. Importantly, mutations in this family of proteins are responsible for approximately 20-30% of all human cancers and 90% of pancreatic cancers. A number of farnesyltransferase inhibitors (FTIs) are currently undergoing evaluation in clinical trials. 2,3 However, these agents have not exhibited significant activity in most patients with Ras-driven tumors 4 due to alternative geranylgeranylation of Ras in FTI treated cells. 5,6 Rce1 and Icmt have been recognized for a number of years as potential alternative anticancer targets to FTase. 7 Although originally thought to be too important for cell viability due to the embryonic lethal phenotype of Rce1 −/− and Icmt −/− mice, 8 10 We have therefore initiated an effort to generate Icmt inhibitors based on the structure of the minimal Icmt substrate N-acetyl-S-farnesyl-Lcysteine (AFC, Figure 2, 1) in hopes of developing potent anticancer agents as well as molecular tools to study the structure and mechanism of Icmt.Recently reported work from our laboratories has shown that selective changes in the farnesyl group of AFC can afford effective inhibitors of yeast Icmt ( The biochemical and cellular effects of other FC analogs have been previously reported. Farnesyl thiosalicylic acid (FTS) has been shown to inhibit the growth of H-Ras-driven Rat1 cells, though it is believed this effect is not solely due to inhib...